Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

23 October 2020

Improving data sharing to increase the efficiency of antibiotic R&D

The authors of this commentary highlight how sharing data can reduce redundancies and accelerate antibacterial R&D, citing the AMR Benchmark as "a good example of how one organisation leveraged its platform to help foster more data sharing".

Direct links

Read the full article

The commentary summarises the threat from AMR and how it is exacerbated by the trend of big pharmaceutical companies leaving the antibiotic market, leaving smaller biotech companies shouldering the burden of antibiotic R&D. There are steps being made to address this market failure, but change is likely to take time. In the meantime, to increase the chance of scientific success for the companies that remain engaged, the authors set out the case for broader data sharing, even by companies that have now left the field.

"Such data sharing is critical to advancing antibiotic discovery efforts, because when projects are discontinued or programmes fail, treasure troves of data may be shelved, locked away or, in some cases, gone forever. Ensuring data are made available in a timely manner, regardless of whether a project continues or concludes, could make a big difference for this resource-strapped field by eliminating unnecessary and wasteful redundancy in the deployment of limited funds."

Authors: Wes Kim, Kevin Krause, Zak Zimmerman & Kevin Outterson

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved